Researchers at the Mucosal Immunology and Biology Research Center (MIBRC) at Massachusetts General Hospital, led by Stefania Seger and CDF Medical Advisory Board member Alessio Fasano, have created 3-D, miniature models of the intestines in order to research celiac disease.
Continue ReadingAfter decades of pleading with our federal government to take celiac disease as seriously as it does other diseases with comparable patient impact, yesterday, the U.S. House and Senate each passed, and President Trump has signed, the FY2020 Federal budget resolution.
Continue ReadingImmunogenX, a clinical stage biotherapeutics company, has published the results of their phase 2 trial testing latiglutenase—an orally administered treatment for celiac disease (CD). Latiglutenase was shown to be safe and effective in reducing the symptoms of seropositive celiac disease patients on a gluten-free diet. A significant improvement in both symptom severity and quality of…
Continue ReadingThere is currently no easy way to diagnose celiac disease in patients already following a gluten-free diet. In order for celiac disease blood tests to be accurate, patients on a gluten-free diet must undergo a “gluten challenge,” a temporary re-introduction of gluten into the diet, by consuming two slices of wheat-based bread daily for 6-8…
Continue ReadingWithin the last year, at least three studies were conducted with the goal of determining the relationship between the amount of gluten ingested and the risk of developing celiac disease. An important review of these studies, conducted by Jonas Ludvigsson and CDF Research Committee Member Benjamin Lebwohl, concluded that new clinical trials must be conducted…
Continue Reading